Canadian Manufacturing

Virox™ announces development of a new disinfectant technology for professional use

Virox's new Citr-IQ disinfectant technology is patented and proven effective against pathogens of concern, including SARS-CoV2, ESBLs, Norovirus, and Candida auris.

April 21, 2022   by CM Staff

OAKVILLE — On Apr. 21, Virox announces its development of Citr-IQ™, a new patented disinfectant technology for professional use.

Citr-IQ is a blend of ingredients that effectively kills pathogens using one of nature’s primary antimicrobials, citric acid, while remaining purportedly gentle on users, materials, and the environment.

“As a research driven company, we are committed to innovating, developing, and improving sustainable disinfectants that allow our users to reduce their environmental impact while providing a superior efficacy and safety profile that disrupts the status quo,” says Randy Pilon, Virox President and CEO. “I challenged our Research & Development team with further advancing our product safety, efficacy, and sustainability beyond that of AHP, and they delivered. Citr-IQ truly represents the next chapter in Virox innovation.”

When asked why citric acid was chosen as an active ingredient, Faraz Alderson, Virox Chief Science Officer, explains, “As a natural compound, citric acid’s characteristics met our stringent criteria of delivering unmatched safety and microbial potency and providing the dual action of cleaning and disinfecting. It was the perfect natural compound to develop our formulations with.”

Advertisement

Citr-IQ’s chemistry is reportedly powerful enough to eliminate pathogens of concern, and its compatibility makes it safer for numerous surfaces and devices and allows for eco-friendly material and packaging options. Further expanding its sustainability profile, Virox mentions that the ingredients in Citr-IQ are biodegradable and non-toxic, having no negative impact on the environment.

“We’ve enhanced the safe and natural disinfecting properties of citric acid to engineer a technology that outperforms other hospital grade disinfectants on the market,” says Lee Nesbitt, Executive Vice President of Commercial Markets. “We have not compromised in its development but have focused on strengthening the ideal disinfectant attributes that set our innovations apart. We are excited to be announcing our new patented technology and working to bring Citr-IQ to Infection Preventionists and their facilities.”

Virox’s new Citr-IQ disinfectant technology is patented and proven effective against pathogens of concern, including SARS-CoV2, ESBLs, Norovirus, and Candida auris, and is the first citric acid-based tuberculocidal disinfectant with a contact time of ≤1-minute. Several Citr-IQ formulations are currently going through regulatory approval by the US EPA and Health Canada, Virox hopes for approval by late 2023.